News | Heart Valve Technology | September 15, 2015

Coramaze Technologies Raises EUR 4.5 Million for Mitramaze Valve Repair System

Money will fund clinical trial of novel transfemoral mitral valve repair system with atraumatic anchoring

September 15, 2015 — coramaze technologies GmbH, a German medical device company, announced the closing of a EUR 4.5 million (US$ 5.15 million) series A financing round for the mitramaze valve repair system. The device is a novel concept for transcatheter mitral valve repair (TMVR) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR).

This round of funding was led by Elron Electronic Industries Ltd., a leading Israeli holding company dedicated to building technology companies, primarily in the field of medical devices. Current investors High-Tech Gründerfonds and SeedCapital Dortmund joined this funding round alongside a pool of private investors.

The mitramaze system is designed for the minimally invasive treatment of one of the most common structural heart valve diseases and aims to improve the treatment for millions of patients suffering from fMR worldwide. The technology is aimed at fMR patients considered unfit for surgery, and has the potential to expand to a broader patient population currently undergoing open heart surgery. The company will use the proceeds of the round to advance the mitramaze implant design concept into a first-in-human clinical investigational study in 2016 and a subsequent feasibility trial to support European CE approval.

Ari Bronshtein, CEO of Elron Electronic Industries Ltd., commented: “We are delighted to announce our investment in coramaze’s pioneering implant design as mitramaze holds the potential to truly improve the standard of care in the field of transcatheter mitral valve repair. We expect that this market will develop into a multi-billion dollar opportunity. coramaze is our first investment in Europe and we are looking forward to supporting the company’s approach with our expertise and strong network.”

Christian Jung, senior investment manager at High-Tech Gründerfonds commented: “mitramaze, by virtue of its design concept, is uniquely qualified to cope with the challenges arising from the high patient-to-patient variability of the anatomy of the mitral valve and the lack of a rigid annulus wall while preserving the natural leaflets of the valve and restoring their functionality. We believe that these properties confer upon mitramaze a major edge over competing technologies and are impressed with the rapid progress made by coramaze since our initial investment in 2014.”

The unique features of the system concept are threefold and reside in its enhanced coaptation design, its exclusive and flexible spacer, and a customized delivery catheter system specifically designed for the transfemoral arterial approach, delivery and implantation of the device. Upon release on-site in the beating heart, the self-expanding implant design allows for an atraumatic anchoring in the left atrium without the need to include adjacent myocardial tissue structures.

For more information: www.coramaze.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init